4 most recent filings and news items mentioning MIRA. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/MIRA/news?limit=20"
Pull MIRA filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayMira Pharmaceuticals announced submission of a Phase 2a clinical trial protocol for Ketamir-2, an oral NMDA receptor modulator, to treat chemotherapy-induced peripheral neuropathy (CIPN), which affects millions of cancer patients annually with no approved therapies. The randomize
View filing at SEC.gov →MIRA Pharmaceuticals entered into a consulting agreement with Andriy Mushak to serve as fractional chief financial officer effective June 6, 2026, providing senior financial leadership for SEC reporting, audit readiness, and capital-markets support. The engagement strengthens the
View filing at SEC.gov →Mira Pharmaceuticals submitted an exhibit filing with the SEC containing contract documentation. The specific terms and business impact require access to the complete exhibit content.
View filing at SEC.gov →Mira Pharmaceuticals submitted an exhibit filing (EX-10.1) with the SEC. The specific content and market impact cannot be determined from the limited document header provided.
View filing at SEC.gov →